All In Biotech

Drug Trial Radar · NCT02601209

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma

A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) VS. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma

Last checked: Nov 20, 2026Latest source record: Aug 23, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 151 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

151

Actual

Start

Nov 30, 2015

Primary completion

Dec 7, 2018

Study completion Jul 11, 2022

Sponsor

Sponsor type
NIH
First posted
Nov 10, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I/II trial studies the side effects and best dose of sapanisertib and to see how well it works compared to pazopanib hydrochloride in treating patients with sarcoma that is too large to be removed (locally advanced) or has spread to other areas of the body (metastatic). Sapanisertib and pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Conditions

  • High Grade Sarcoma
  • Metastatic Leiomyosarcoma
  • Metastatic Malignant Peripheral Nerve Sheath Tumor
  • Metastatic Synovial Sarcoma
  • Metastatic Undifferentiated Pleomorphic Sarcoma
  • Metastatic Unresectable Sarcoma
  • Myxofibrosarcoma
  • Recurrent Leiomyosarcoma
  • Recurrent Malignant Peripheral Nerve Sheath Tumor
  • Recurrent Synovial Sarcoma
  • Recurrent Undifferentiated Pleomorphic Sarcoma
  • Stage III Uterine Corpus Leiomyosarcoma AJCC v8
  • Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8
  • Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8
  • Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8
  • Stage IV Uterine Corpus Leiomyosarcoma AJCC v8
  • Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8
  • Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8
  • Unresectable Leiomyosarcoma

Interventions

  • PazopanibDrug

    Given PO

  • Pazopanib HydrochlorideDrug

    Given PO

  • SapanisertibDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Phase I Participants With Dose-Limiting Toxicity Events (Phase I)Time frame: 28 days
  2. Progression-free Survival (PFS) (Phase II Analysis Group 2 - Initial Treatment Period)Time frame: Up to 2 years

Locations

460 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama

  • Anchorage Associates in Radiation Medicine

    Anchorage, Alaska

  • Anchorage Radiation Therapy Center

    Anchorage, Alaska

  • Alaska Breast Care and Surgery LLC

    Anchorage, Alaska

  • Alaska Oncology and Hematology LLC

    Anchorage, Alaska

  • Alaska Women's Cancer Care

    Anchorage, Alaska

  • Anchorage Oncology Centre

    Anchorage, Alaska

  • Katmai Oncology Group

    Anchorage, Alaska

  • Providence Alaska Medical Center

    Anchorage, Alaska

  • Banner University Medical Center - Tucson

    Tucson, Arizona

  • University of Arizona Cancer Center-North Campus

    Tucson, Arizona

  • CHI Saint Vincent Cancer Center Hot Springs

    Hot Springs, Arkansas

  • PCR Oncology

    Arroyo Grande, California

  • Sutter Auburn Faith Hospital

    Auburn, California

  • Sutter Cancer Centers Radiation Oncology Services-Auburn

    Auburn, California

  • Alta Bates Summit Medical Center-Herrick Campus

    Berkeley, California

  • Providence Saint Joseph Medical Center/Disney Family Cancer Center

    Burbank, California

  • Mills-Peninsula Medical Center

    Burlingame, California

  • Sutter Cancer Centers Radiation Oncology Services-Cameron Park

    Cameron Park, California

  • Eden Hospital Medical Center

    Castro Valley, California

  • Sutter Davis Hospital

    Davis, California

  • Palo Alto Medical Foundation-Fremont

    Fremont, California

  • Los Angeles County-USC Medical Center

    Los Angeles, California

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California

  • Memorial Medical Center

    Modesto, California

  • Palo Alto Medical Foundation-Camino Division

    Mountain View, California

  • Palo Alto Medical Foundation-Gynecologic Oncology

    Mountain View, California

  • USC Norris Oncology/Hematology-Newport Beach

    Newport Beach, California

  • Sutter Cancer Research Consortium

    Novato, California

  • Palo Alto Medical Foundation Health Care

    Palo Alto, California

  • Keck Medical Center of USC Pasadena

    Pasadena, California

  • Sutter Cancer Centers Radiation Oncology Services-Roseville

    Roseville, California

  • Sutter Roseville Medical Center

    Roseville, California

  • Sutter Medical Center Sacramento

    Sacramento, California

  • California Pacific Medical Center-Pacific Campus

    San Francisco, California

  • Palo Alto Medical Foundation-Santa Cruz

    Santa Cruz, California

  • Sutter Pacific Medical Foundation

    Santa Rosa, California

  • Palo Alto Medical Foundation-Sunnyvale

    Sunnyvale, California

  • Sutter Cancer Centers Radiation Oncology Services-Vacaville

    Vacaville, California

  • Sutter Solano Medical Center/Cancer Center

    Vallejo, California

Showing 40 of 460 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.